Analysis On The Motivation,Path And Financial Performance Of The Return Of Mindray Medical

In the 1990s,as China’s capital market just started,A-share market had limited capacity and strict listing requirements,while the financial market mechanism and system of the United States were relatively perfect,so many domestic enterprises went to the United States to get listed,which were collectively referred to as "Chinese concept stocks",or Chinese concept stocks for short.In 2010,due to the frequent occurrence of "short selling" by Muddy Waters and the questioning of the VIE model,the stock price of Chinese general stocks fell sharply.In 2015,the market value of many Chinese concept stocks was seriously undervalued in the US stock market,which led to a delisting boom.In 2020,after the financial fraud incident of Luckin Coffee,more Chinese concept stocks were blocked by short sellers.Moreover,the US Senate passed the Foreign Company Accountability Act,which targeted Chinese concept stocks directly.With the introduction of a series of favorable policies in recent years,the science and technology innovation board and the growth enterprise board carry out the "registration system" reform,which is undoubtedly great good news for many Chinese concept stocks,thus it can be seen that the return of Chinese concept stocks has been the general trend.Mindray Medical,as a senior Chinese stock with 10 years of overseas listing experience,its regression motivation,path selection and financial performance analysis have certain reference value for other Chinese stock preparing to return.Under the background of listing Chinese general shares in the United States--delisting overseas--returning to A-share re-listing,this paper,based on relevant theories such as information asymmetry and regulation avoidance,and taking Mindray Medical as an example,mainly studies A series of issues such as the motivation,path and financial performance of Chinese general shares returning.First of all,this paper introduces the general situation of overseas listing and delisting of Chinese concept stocks,as well as the sectors and paths of domestic A-share listing,and gives A detailed explanation in combination with the latest policies.Then through combing the Mindray medical to listing to the whole process of privatization to return to A shares,its after privatization-demolition of the red-chip architecture-return to a-share market,analysis of Mindray medical return the five motivations of domestic capital markets,including the enterprise value is undervalued,A short-seller attack,listed the cost is high,the rush to strategic transformation as well as the domestic good policy guidance.Then it analyzes the reasons why it chooses IPO as the regression path to go public.Finally,with the help of traditional financial analysis and new EVA analysis,that is,financial index analysis,Du Pont analysis and EVA value analysis,the overall analysis of its financial performance before and after the regression,and the vertical and horizontal comparison with the same industry.Through the overall analysis of Mindray Medical,it is found that Mindray Medical has indeed improved its financial performance after its return.Reasonable motivation and appropriate IPO return path have improved its market value,stock price and other indicators,optimized the resource allocation and governance structure,and brought a positive impact on the enterprise as a whole.